The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Frequency distribution of SPARC in triple-negative breast cancer patients.
G. Basu
Employment or Leadership Position - Caris Life Sciences
G. Van Vickle
Employment or Leadership Position - Caris Life Sciences
Research Funding - Caris Life Sciences
A. Ghazalpour
Employment or Leadership Position - Caris Life Sciences
R. Ashfaq
Employment or Leadership Position - Caris Life Sciences
Stock Ownership - Caris Life Sciences (B)
Honoraria - Genentech
Other Remuneration - Caris Life Sciences
Z. Gatalica
Employment or Leadership Position - Caris Life Sciences
R. Blevins
Employment or Leadership Position - Caris Life Sciences
D. Arguello
Employment or Leadership Position - Caris Life Sciences
L. Brisbin
No relevant relationships to disclose
C. Roberts
Employment or Leadership Position - Caris Life Sciences
Stock Ownership - Caris Life Sciences
D. Loesch
Employment or Leadership Position - Caris Life Sciences
Stock Ownership - Caris Life Sciences
R. Bender
Employment or Leadership Position - Caris Life Sciences